Home LiteratureArticle Details
PMID: 23564750 Published · ppublish English

Evaluating the performance of the breast cancer genetic risk models BOADICEA, IBIS, BRCAPRO and Claus for predicting BRCA1/2 mutation carrier probabilities: a study based on 7352 families from the German Hereditary Breast and Ovarian Cancer Consortium.

Journal of medical genetics ·Vol. 50 ·No. 6 ·2013-12-09

Fischer Christine, Kuchenbäcker Karoline, Engel Christoph, Zachariae Silke, Rhiem Kerstin, Meindl Alfons, Rahner Nils, Dikow Nicola, Plendl Hansjörg, Debatin Irmgard, Grimm Tiemo, Gadzicki Dorothea, Flöttmann Ricarda, Horvath Judit, Schröck Evelin, Stock Friedrich, Schäfer Dieter, Schwaab Ira, Kartsonaki Christiana, Mavaddat Nasim, Schlegelberger Brigitte, Antoniou Antonis C, Schmutzler Rita,

Abstract

Risk prediction models are widely used in clinical genetic counselling. Despite their frequent use, the genetic risk models BOADICEA, BRCAPRO, IBIS and extended Claus model (eCLAUS), used to estimate BRCA1/2 mutation carrier probabilities, have never been comparatively evaluated in a large sample from central Europe. Additionally, a novel version of BOADICEA that incorporates tumour pathology information has not yet been validated.,Using data from 7352 German families we estimated BRCA1/2 carrier probabilities under each model and compared their discrimination and calibration. The incremental value of using pathology information in BOADICEA was assessed in a subsample of 4928 pedigrees with available data on breast tumour molecular markers oestrogen receptor, progesterone receptor and human epidermal growth factor 2.,BRCAPRO (area under receiver operating characteristic curve (AUC)=0.80 (95% CI 0.78 to 0.81)) and BOADICEA (AUC=0.79 (0.78-0.80)), had significantly higher diagnostic accuracy than IBIS and eCLAUS (p<0.001). The AUC increased when pathology information was used in BOADICEA: AUC=0.81 (95% CI 0.80 to 0.83, p<0.001). At carrier thresholds of 10% and 15%, the net reclassification index was +3.9% and +5.4%, respectively, when pathology was included in the model. Overall, calibration was best for BOADICEA and worst for eCLAUS. With eCLAUS, twice as many mutation carriers were predicted than observed.,Our results support the use of BRCAPRO and BOADICEA for decision making regarding genetic testing for BRCA1/2 mutations. However, model calibration has to be improved for this population. eCLAUS should not be used for estimating mutation carrier probabilities in clinical settings. Whenever possible, breast tumour molecular marker information should be taken into account.

Keywords
Cancer: breast Clinical genetics Genetic screening/counselling Prevention Screening
Article Info
Journal
Journal of medical genetics
Abbr.
J Med Genet
Published
2013-12-09
Indexed
2013-05-15
Updated
2016-11-22
Language
English
Country/Region
England
NLM ID
2985087R
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com